FY2024 Earnings Forecast for TCRX Issued By Lifesci Capital

TScan Therapeutics, Inc. (NASDAQ:TCRX) – Equities research analysts at Lifesci Capital dropped their FY2024 earnings per share (EPS) estimates for TScan Therapeutics in a research note issued on Tuesday, November 12th. Lifesci Capital analyst S. Slutsky now expects that the company will earn ($1.08) per share for the year, down from their previous estimate of ($1.07). The consensus estimate for TScan Therapeutics’ current full-year earnings is ($1.17) per share. Lifesci Capital also issued estimates for TScan Therapeutics’ FY2025 earnings at ($1.08) EPS.

Other research analysts also recently issued reports about the company. Wedbush restated an “outperform” rating and set a $10.00 price objective on shares of TScan Therapeutics in a report on Tuesday, November 5th. HC Wainwright restated a “buy” rating and set a $15.00 price objective on shares of TScan Therapeutics in a report on Friday. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 target price on shares of TScan Therapeutics in a research report on Tuesday. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, TScan Therapeutics presently has an average rating of “Buy” and a consensus target price of $12.00.

TScan Therapeutics Trading Down 8.5 %

Shares of NASDAQ TCRX opened at $4.41 on Friday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 7.77 and a current ratio of 9.56. The business’s 50 day moving average price is $5.31 and its 200-day moving average price is $6.49. TScan Therapeutics has a fifty-two week low of $3.73 and a fifty-two week high of $9.69. The company has a market cap of $233.62 million, a price-to-earnings ratio of -4.16 and a beta of 0.79.

Insider Buying and Selling at TScan Therapeutics

In other TScan Therapeutics news, Director Barbara Klencke acquired 5,000 shares of the stock in a transaction dated Friday, August 23rd. The stock was purchased at an average price of $5.69 per share, with a total value of $28,450.00. Following the transaction, the director now directly owns 35,000 shares of the company’s stock, valued at $199,150. This trade represents a 16.67 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Zoran Zdraveski sold 164,686 shares of the firm’s stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $5.78, for a total value of $951,885.08. Following the completion of the sale, the insider now directly owns 4,716 shares of the company’s stock, valued at $27,258.48. The trade was a 97.22 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have purchased 15,000 shares of company stock valued at $82,550. 2.76% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On TScan Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP purchased a new position in shares of TScan Therapeutics during the 2nd quarter valued at about $70,000. SG Americas Securities LLC purchased a new position in shares of TScan Therapeutics in the 3rd quarter valued at about $78,000. The Manufacturers Life Insurance Company purchased a new position in shares of TScan Therapeutics in the 2nd quarter valued at about $90,000. XTX Topco Ltd purchased a new position in shares of TScan Therapeutics in the 3rd quarter valued at about $112,000. Finally, MetLife Investment Management LLC increased its stake in shares of TScan Therapeutics by 129.1% in the 3rd quarter. MetLife Investment Management LLC now owns 23,363 shares of the company’s stock valued at $116,000 after purchasing an additional 13,164 shares in the last quarter. Hedge funds and other institutional investors own 82.83% of the company’s stock.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.